Akari Therapeutics (NASDAQ: AKTX) holder reports 8.9% ownership

Rhea-AI Filing Summary

Akari Therapeutics investor Ray Prudo has updated his ownership in a Schedule 13D/A Amendment No. 10. He is reported to beneficially own 8,391,326,467 ordinary shares, representing 8.9% of Akari’s ordinary shares, based on 91,567,009,533 shares outstanding as of March 1, 2026.

The filing reflects December 17, 2025 transactions where Dr. Prudo purchased Series G Warrants and Pre-Funded Warrants in a private placement and additional Note Exchange Warrants and Pre-Funded Warrants in a note cancellation and exchange, all at a combined price of $0.4041 per warrant pair, using personal funds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 10)

Akari Therapeutics Plc

(Name of Issuer)

Ordinary Shares, $0.000000005 par value

(Title of Class of Securities)

Win Rutherfurd, Esq.
Greenberg Traurig, LLP, One Vanderbilt Avenue
New York, NY, 10017
(212) 801-9200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

03/02/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Ray Prudo, M.D.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,551,850,267.00
8	Shared Voting Power 839,476,200.00
9	Sole Dispositive Power 7,551,850,267.00
10	Shared Dispositive Power 839,476,200.00

11

Aggregate amount beneficially owned by each reporting person

8,391,326,467.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.9 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares. 2) Includes (i) 5,163,920,600 shares held of record by Reporting Person, (ii) 377,291,667 shares underlying options exercisable within 60 days of March 1, 2026 granted to Reporting Person, (iii) 2,010,638,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 (iii) 800,766,600 shares held of record by RPC Pharma Limited ("RPC") and (iv) 38,709,600 ordinary shares held of record by Praxis Trustees Limited as trustee of The Sonic Healthcare Holding Company ("Praxis"). Excludes up to 5,721,437,500 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Reporting Person which are subject to a 9.99% beneficial ownership limitation and with respect to which Reporting Person disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and Praxis and thereby may be deemed the beneficial owner of such shares. 3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

RPC Pharma Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

MALTA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 800,766,600.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 800,766,600.00

11

Aggregate amount beneficially owned by each reporting person

800,766,600.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.87 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares. 2) Includes 800,766,600 shares held of record by RPC. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and thereby may be deemed the beneficial owner of such shares. 3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

GUERNSEY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 38,709,600.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 38,709,600.00

11

Aggregate amount beneficially owned by each reporting person

38,709,600.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.042 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

1) Comprised of the Registrant's ordinary shares, $0.000000005 par value per share ("Ordinary Shares"), represented by American Depositary Shares ("ADSs"). Each ADS represents 2,000 Ordinary Shares. 2) Includes 38,709,600 ordinary shares held of record by Praxis. Reporting Person controls the voting and investment decisions with respect to the shares held of record by Praxis and thereby may be deemed the beneficial owner of such shares. 3) The percentage of ownership is based on 91,567,009,533 ordinary shares issued and outstanding on March 1, 2026, as per information provided to the Reporting Person by the Issuer.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, $0.000000005 par value
(b)	Name of Issuer: Akari Therapeutics Plc
(c)	Address of Issuer's Principal Executive Offices: 401 East Jackson Street, Suite 3300, Tampa, FLORIDA , 33602.
Item 1 Comment: This Amendment No. 10 to Schedule 13D ("Amendment No. 10") amends and supplements where indicated the Statement on Schedule 13D originally filed with the Securities and Exchange Commission on September 29, 2015 and amended on October 26, 2017, March 30, 2020, October 18, 2021, January 14, 2022, April 14, 2023, October 20, 2023, January 4, 2024, June 20, 2024 and February 14, 2025, respectively (collectively, the "Prior Schedule 13D") by and on behalf of RPC Pharma Limited, a Maltese corporation ("RPC"), Ray Prudo, M.D., a citizen of Canada ("Dr. Prudo") and Praxis Trustees Limited As trustee of The Sonic Healthcare Holding Company ("Praxis," and together with RPC, and Dr. Prudo, the "Reporting Persons"), and relates to the ordinary shares, $0.000000005 par value ("Ordinary Shares") of Akari Therapeutics, Plc, a public limited company formed under the laws of England and Wales (the "Issuer"). The Issuer's American Depositary Shares, each representing 2,000 Ordinary Shares (the "ADSs"), have been registered on a registration statement on Form F-6 (File No. 333-185197), as supplemented (File Nos. 333-234213, 333-262049 and 333-185197), and trade on the Nasdaq Capital Market under the symbol "AKTX." Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Prior Schedule 13D. This Amendment No. 10 amends and supplements the Prior Schedule 13D as specifically set forth herein. Except as set forth below, all previous Items in the Prior Schedule 13D remain unchanged. This Amendment No. 10 is being filed to amend Items 3, 4 and 5 as set forth below and to update the number of shares of Ordinary Shares beneficially held by the Reporting Persons as a result of the transaction described below.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Prior Schedule 13D is hereby supplemented by adding the following paragraph: On December 17, 2025, the Issuer closed a private placement of the Issuer's securities (the "December 2025 PIPE"), pursuant to which, Dr. Prudo purchased 618,658 Series G Warrants to purchase ADSs (representing 1,237,316,000 Ordinary Shares) and 618,658 Pre-Funded Warrants to purchase ADSs (representing 1,237,316,000 Ordinary Shares) at a combined price of $0.4041 per Series G Warrant and Pre-Funded Warrant. On the same date, the Issuer closed a note cancellation and exchange agreement, pursuant to which, Dr. Prudo purchased 386,661 Note Exchange Warrants to purchase ADSs (representing 773,322,000 Ordinary Shares) and 618,658 Pre-Funded Warrants to purchase ADSs (representing 773,322,000 Ordinary Shares) at a combined price of $0.4041 per Note Exchange Warrant and Pre-Funded Warrant. The funds used by Dr. Prudo to acquire the ADSs were from his personal funds.
Item 4.	Purpose of Transaction
	On December 17, 2025, Dr. Prudo purchased the securities described in the transactions as described in Item 3 above.
Item 5.	Interest in Securities of the Issuer
(a)	Dr. Prudo, either in his individual capacity or as sole manager and member of RPC and Praxis, respectively, beneficially owns an aggregate of (i) 5,163,920,600 shares held of record by Dr. Prudo, (ii) 377,291,667 shares underlying options exercisable within 60 days of March 1, 2026 granted to Dr. Prudo, (iii) 2,010,638,000 shares underlying prefunded warrants exercisable within 60 days of March 1, 2026 (iii) 800,766,600 shares held of record by RPC and (iv) 38,709,600 ordinary shares held of record by Praxis. Excludes up to 5,721,437,500 shares underlying warrants exercisable within 60 days of March 1, 2026 issued to Reporting Person which are subject to a 9.99% beneficial ownership limitation and with respect to which Reporting Person disclaims beneficial ownership to the extent that any exercise of such warrants would exceed such percentage. Reporting Person controls the voting and investment decisions with respect to the shares held of record by RPC and Praxis and thereby may be deemed the beneficial owner of such shares.
(b)	See Rows 7 through 11 of cover page for Reporting Persons.
(c)	None of the Reporting Persons has effected any transactions in Ordinary Shares during the 60 days prior to the filing of this Amendment No. 10.
(d)	No person other than the Reporting Persons is known to have the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of any Ordinary Shares.
(e)	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ray Prudo, M.D.

Signature:	/s/ Ray Prudo, M.D.
Name/Title:	Ray Prudo, Reporting Person
Date:	03/04/2026

RPC Pharma Limited

Signature:	/s/ Ray Prudo, M.D.
Name/Title:	Ray Prudo, Reporting Person
Date:	03/04/2026

Praxis Trustees Limited as trustee of the Sonic Healthcare Holding Company

Signature:	/s/ Jodie Travers
Name/Title:	Director for and on behalf of Praxis Trustees Limited
Date:	03/04/2026

Signature:	/s/ Tom Zierer
Name/Title:	Director for and on behalf of Praxis Trustees Limited
Date:	03/04/2026

FAQ

What does Akari Therapeutics (AKTX) Schedule 13D/A Amendment No. 10 report?

The amendment reports updated beneficial ownership for investor Ray Prudo. It reflects his 8.9% stake in Akari Therapeutics’ ordinary shares and details December 17, 2025 warrant and pre-funded warrant purchases in a private placement and note exchange funded with his personal capital.

How many Akari Therapeutics shares does Ray Prudo beneficially own?

Ray Prudo is reported to beneficially own 8,391,326,467 Akari ordinary shares. This total includes shares held directly, options, prefunded warrants, and shares held through RPC Pharma Limited and Praxis Trustees Limited, and represents 8.9% of the ordinary shares outstanding on March 1, 2026.

What transactions on December 17, 2025 are described for Akari Therapeutics (AKTX)?

On December 17, 2025, Akari closed a private placement and a note cancellation and exchange. In these, Ray Prudo bought Series G Warrants, Note Exchange Warrants, and Pre-Funded Warrants to purchase ADSs representing ordinary shares, at a combined price of $0.4041 per warrant pair.

How is the 8.9% ownership of Akari Therapeutics by Ray Prudo calculated?

The 8.9% figure is based on 91,567,009,533 Akari ordinary shares outstanding on March 1, 2026. His beneficial holdings of 8,391,326,467 shares, including direct holdings, options, prefunded warrants, and shares via RPC and Praxis, are compared to that total share count to derive the percentage.

What role do RPC Pharma Limited and Praxis Trustees play in Akari Therapeutics ownership?

RPC Pharma Limited holds 800,766,600 Akari ordinary shares and Praxis Trustees Limited holds 38,709,600. The filing states that Ray Prudo controls voting and investment decisions for shares held by RPC and Praxis, so he may be deemed the beneficial owner of those positions in addition to his direct holdings.

What are the key warrant positions disclosed for Akari Therapeutics (AKTX)?

The filing notes prefunded warrants and other warrants exercisable within 60 days of March 1, 2026, representing billions of ordinary shares. It also states that additional warrants for up to 5,721,437,500 shares are subject to a 9.99% beneficial ownership limitation and are excluded from reported beneficial ownership.